Last reviewed · How we verify

NCT05229575: BoMB

Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients

Status unknown NA Last updated 8 February 2022
What this trial tests

NA trial testing Stereotactic Body Radiation Therapy (SBRT) in Stage IV Breast Cancer in 30 participants. Status unknown.

Timeline
10 July 2020
Primary endpoint
10 October 2022
10 April 2023

Quick facts

Lead sponsorCampus Bio-Medico University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date10 July 2020
Primary completion10 October 2022
Estimated completion10 April 2023
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Campus Bio-Medico University

Who can join

18 and older, female only, with Stage IV Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a dose escalation study involving stage IV breast cancer patients not progressing after 6 months of first line systemic treatment. Potential advantages of stereotactic body radiotherapy (SBRT) in treating breast primary tumor in metastatic breast cancer are: * radio-biological advantage of a short highly effective treatment schedule * possibility of preventing lesions to become symptomatic * possibility of continuing systemic treatment without interruption

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. BOMB trial: First results of stereotactic radiotherapy to primary breast tumor in metastatic breast cancer patients.
    Ippolito E, Silipigni S, Pantano F, Matteucci P, et al · · 2023 · cited 7× · PMID 37007063 · DOI 10.3389/fonc.2023.1062355

Verify or expand the search:

Other trials of Stereotactic Body Radiation Therapy (SBRT)

Trials testing the same drug.

Other recruiting trials for Stage IV Breast Cancer

Currently open trials in the same condition.

Other Campus Bio-Medico University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05229575.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing